MoonLake Immunotherapeutics
MLTX
MLTX
115 hedge funds and large institutions have $3.43B invested in MoonLake Immunotherapeutics in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 31 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
9% more capital invested
Capital invested by funds: $3.14B → $3.43B (+$294M)
6% more funds holding
Funds holding: 109 → 115 (+6)
1.55% more ownership
Funds ownership: 99.02% → 100.57% (+1.5%)
Holders
115
Holding in Top 10
6
Calls
$11.3M
Puts
$8.56M
Top Buyers
| 1 | +$75.3M | |
| 2 | +$45.5M | |
| 3 | +$32.5M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.7M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$18M |
Top Sellers
| 1 | -$108M | |
| 2 | -$19M | |
| 3 | -$12.4M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.32M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.37M |